Cadence Launches ROCS X AI Platform for Drug Discovery, Enabling Trillion-Molecule Virtual Screening
核心洞察
Cadence Molecular Sciences (搜索) unveiled ROCS X (搜索), an AI-enabled virtual screening platform that allows scientists to conduct 3D searches across trillions of drug-like molecules for accelerated drug discovery.
Treeline Biosciences (搜索) validated the technology by identifying over 150 novel synthesizable drug candidates in previously unexplored chemical space across multiple cancer (搜索)-focused projects.
The platform delivers performance improvements of at least three orders of magnitude over current approaches, with validation studies showing 97% accuracy in molecular identification.
Cadence Molecular Sciences (搜索) announced the launch of ROCS X (搜索), a breakthrough AI-enabled virtual screening solution that enables scientists to conduct 3D searches across trillions of drug-like molecules. The technology was unveiled at miniCUP Boston and represents a significant advancement in computational drug discovery capabilities.
The platform was developed and validated through collaboration with Treeline Biosciences (搜索), a biotechnology company focused on addressing serious medical conditions including cancer (搜索). Using ROCS X (搜索), Treeline has successfully identified and physically sourced over 150 novel compounds for evaluation as potential drug candidates.
Revolutionary Scale and Performance
ROCS X (搜索) achieves unprecedented scale by building on the Cadence (搜索) Orion Molecular Design Platform, combining proven OpenEye OMEGA conformer generation and ROCS (Rapid Overlay of Chemical Structures) virtual screening software with AI-enabled 3D search capabilities. This integration delivers reliable, efficient, and computationally affordable shape and electrostatic overlays from trillions of molecules.
"We were challenged by Treeline Biosciences (搜索) to build and create search capabilities for databases of 3D synthetically accessible drug-like molecules at an unprecedented scale," said Geoff Skillman, vice president of Research & Development at Cadence Molecular Sciences (搜索). "Industry data shows—and we continue to demonstrate—that searching a larger chemical space yields more diverse compounds and more unique scaffolds, enabling customers to accelerate discovery of potential drug candidates."
The platform delivers a performance increase of at least three orders of magnitude over current approaches by creating 3D representations of molecules along with electrostatics. This advancement significantly outperforms other technologies that claim 3D search capabilities or rely on feature trees.
Clinical Validation and Impact
Treeline Biosciences (搜索) has demonstrated the practical value of ROCS X (搜索) across multiple drug discovery projects. "Using Cadence ROCS X, scientists at Treeline can now search trillions of drug-like molecules—an achievement that was unimaginable just a few years ago," said Eric Manas, senior vice president of Medicine Design at Treeline Biosciences. "By running ROCS X, we've identified novel chemical matter leading to promising 3D ligand-protein structures across multiple drug discovery projects."
In validation experiments, ROCS X (搜索) was compared to traditional FastROCS enumerated search methods and demonstrated 97% accuracy in identifying identical molecules from a test set of 1,000 compounds. The technology enables customers to search over a thousand times more molecules in the synthon space compared to previous methods.
Synthetic Success and Target Engagement
Treeline has identified a variety of molecules through ROCS X (搜索) with consistently high synthetic success rates and has obtained multiple experimental structures showing hits bound to their intended targets. This validation demonstrates the platform's ability to identify not only novel chemical matter but also compounds that can be successfully synthesized and show meaningful biological activity.
Availability and Access
Early access to ROCS X (搜索) is currently available, with general availability expected in the first quarter of 2026. Scientists interested in advanced access can contact the development team through established channels. The platform represents a significant step forward in computational drug discovery, potentially accelerating the identification of novel therapeutic compounds across multiple disease areas.